Genocea Biosciences
Investor Relations Department
100 Acom Park Drive, 5th Floor
Cambridge, MA 02140
United States

Visit IR website
Sign-up for Email alerts

NASDAQ: GNCA	
Last Trade:	6.39
Trade Time:	4:00 PM ET Apr 28, 2017
Change:	0.14 (+2.240%)
Day Range	6.16 - 6.50
52-Week Range	3.28 - 7.29
Volume	165,387

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Genocea aims to transform vaccine discovery and development to improve millions of lives. We use ATLAS™, our proprietary technology platform that rapidly identifies T cell antigens associated with protective immune responses in humans exposed to a pathogen. We have a pipeline of novel vaccine candidates that stimulate the T cell arm of the immune system, which is increasingly recognized as critical to generating protective immunity against a wide array of diseases. Genocea's pipeline includes clinical programs addressing genital herpes and pneumococcus and research efforts in... (more)

Stock Performance

Press Releases [View all]

Apr 27, 2017
Genocea to Host First Quarter 2017 Financial Results Conference Call & Webcast on May 4, 2017 at 9 a.m. ET

Apr 11, 2017
Genocea Awarded World Vaccine Congress 2017 Industry Excellence Award for Best Therapeutic Vaccine for GEN-003 for Genital Herpes

Mar 29, 2017
Genocea to Present at the 16th Annual Needham Healthcare Conference

Mar 6, 2017
Howard Mayer, M.D., of Shire, Joins Genocea Biosciences' Board of Directors

Mar 1, 2017
Genocea to Present at the Cowen and Company 37th Annual Health Care Conference

Upcoming Events [View all]

May 4, 2017 9:00 AM ET
First Quarter 2017 Financial Results

Financials [View all]

Fourth Quarter Financial Results

Feb 17, 2017
Annual Report (10-K)

Apr 21, 2017
Proxy Statement (DEF 14A)

Nov 4, 2016
Quarterly Report (10-Q)

Aug 5, 2016
Quarterly Report (10-Q)

May 6, 2016
Quarterly Report (10-Q)